• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
    • Our history
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Bios September 8, 2021

Carol Green

Senior Director, Preclinical Development

Carol Green, Ph.D., DABT, is an accomplished scientist with expertise in toxicology, absorption, distribution, metabolism, and excretion studies. In her current role, she is the principal investigator for four National Institutes of Health contracts and one research grant.

Her research includes developing new in vitro human tissue models to predict toxicity of pharmaceuticals and environmental chemicals, and advancing the preclinical development of promising pharmaceutical candidates against chemical threat agents. She also provides preclinical pharmacology and toxicology data on anti-infective agents, cancer chemopreventive and therapeutic agents, and other pharmaceuticals. Green oversees the development of data included in Investigational New Drug applications and has served on project teams for more than 10 drugs that have moved into Phase I trials.

Green has authored or co-authored 57 published papers and 98 abstracts. She is a diplomate for the American Board of Toxicology, and past president of the Genetic and Environmental Toxicology Association of Northern California. She received a Ph.D. in pharmacology and toxicology from the University of California, Davis, and conducted postdoctoral work in biochemical toxicology at SRI.

Recent publications

more +
  • A tandem liquid chromatography and tandem mass spectrometry (LC/LC–MS/MS) technique to separate and quantify steroid isomers 11β-methyl-19-nortestosterone and testosterone 

    Here we describe a high-sensitivity LC/LC-MS/MS method that combines chiral chromatography and reverse-phase chromatography.

  • Pharmacokinetics and Safety Studies in Rodent Models Support Development of EPICERTIN as a Novel Topical Wound-Healing Biologic for Ulcerative Colitis 

    This study established for the first time the pharmacokinetics, bioavailability, and acute safety of EPICERTIN in healthy and dextran sodium sulfate-induced colitic mice and healthy rats.

  • Enhancement of sensitivity and quantification quality in the LC-MS/MS measurement of large biomolecules with sum of MRM (SMRM)

    We describe here an approach to boost detection sensitivity and expand dynamic range in the quantitation of large molecules while maintaining analytical specificity using summation of MRM (SMRM) transitions and LC separation technique.

  • Pharmacokinetics and Metabolism of 4R-Cembranoid

    The purpose of this study was to examine the metabolism and pharmacokinetics of 4R as part of its preclinical development as a neuroprotective drug.

  • Formulation Approaches to Improving the Delivery of an Antiviral Drug with Activity against Seasonal Flu

    The main objective of the present study was to develop formulations of noscapine hydrochloride hydrate with enhanced solubility and bioavailability using co-solvent- and cyclodextrin-based approaches.

  • Nitrocobinamide, a New Cyanide Antidote That Can Be Administered by Intramuscular Injection

    Here we show that adding sodium nitrite to cobinamide yields a stable derivative that rescues cyanide-poisoned mice and rabbits when given by intramuscular injection.

Career call to action image

Work with us

Search jobs

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2023 SRI International
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}